Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826451 | 0.79 | MEN1 (0.38) | — | |
| SCHEMBL25826362 | 0.77 | CYP17A1 (0.49) | UHRF1TYMSNOS3NOS1NOS2 | |
| SCHEMBL22152377 | 0.76 | MPO (0.43) | UHRF1TYMSKCNQ2GRM5FLT1 | |
| SCHEMBL25826381 | 0.73 | PIK3CB (0.38) | UHRF1TYMSNOS3NOS1NOS2 | |
| SCHEMBL24671918 | 0.72 | UHRF1 (0.44) | UHRF1NOS3NOS2KCNQ2GRM5 | |
| SCHEMBL12362963 | 0.71 | CYP3A4 (0.52) | UHRF1NOS3NOS1NOS2KCNQ2 | |
| SCHEMBL25826450 | 0.70 | SMN1; SMN2 (0.37) | KCNQ2 | |
| SCHEMBL21982559 | 0.70 | MPO (0.44) | UHRF1KCNQ2GRM5FLT1KDR | |
| SCHEMBL11229303 | 0.69 | MAP4K4 (0.60) | UHRF1MAP4K4TLR7PIK3CB | |
| SCHEMBL20756914 | 0.69 | UHRF1 (0.46) | UHRF1KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | UHRF1 3902/4885TYMS 3169/4885NOS3 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.